Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
meso-CART in Advanced Pancreatic Carcinoma
NCT02706782Phase 1Unknown
- Sponsor
- Shanghai Genechem
- Start
- Mar 2016
- Primary completion
- Feb 2018
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAI-meso-CART in pancreatic carcinoma, sponsored by Shanghai Genechem. Primary endpoint: Number of patients with adverse event at 6 weeks. Status: unknown.
02
Drugs
TAI-meso-CART
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT02706782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706782.